Mirap Distab (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing postsynaptic 5‑HT2 and 5‑HT3 receptors. This dual action enhances serotonergic and noradrenergic neurotransmission, contributing to its antidepressant effect.

The appropriate dose of Mirap Distab is determined by the prescribing clinician based on the individual’s clinical condition, age, and response to therapy. Dosing typically starts at a low level and may be titrated upward as needed, under medical supervision.

Safety data for mirtazapine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Mirap Distab, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in greater sedation and weight gain but may be advantageous for patients with insomnia or poor appetite. Its efficacy in major depressive disorder is comparable, while its side‑effect profile differs.

Mirap Distab should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure they are out of reach of children.

Mirap Distab is taken orally, usually as a tablet. It should be swallowed whole with water, preferably in the evening due to its sedative effect, unless otherwise directed by a healthcare provider.

Serious risks include agranulocytosis or severe neutropenia, seizures, marked hypotension, hepatic dysfunction, and the emergence or worsening of suicidal thoughts, particularly during the early phase of treatment. Patients should be monitored closely for these events.

Mirap Distab is contraindicated in patients with known hypersensitivity to mirtazapine, those who have taken a monoamine oxidase inhibitor within the past 14 days, and individuals with severe hepatic impairment. Caution is also advised for patients with uncontrolled cardiovascular disease.